Geneva, Switzerland — The World Health Organization has issued a global alert concerning three contaminated cough syrups produced in India, which are linked to a tragic rise in childhood fatalities. The alert marks another serious concern amid ongoing quality-control issues in pharmaceutical manufacturing that have previously resulted in the deaths of numerous children.
The WHO identified batches of three specific products—Coldrif, Respifresh TR, and ReLife—manufactured by Sresan Pharmaceutical, Rednex Pharmaceuticals, and Shape Pharma. These syrups, intended for the relief of coughs, colds, and flu symptoms, reportedly contain diethylene glycol, a toxic chemical that has been associated with other harmful incidents involving Indian-made pharmaceuticals in recent years.
Reports indicate that at least 22 children in Madhya Pradesh, a central state in India, have succumbed after consuming these contaminated products. The Central Drugs Standard Control Organization, India’s health regulatory authority, has confirmed the presence of diethylene glycol in the syrups. This hazardous substance has raised alarms previously, as it was implicated in over 60 child deaths in Gambia linked to similar Indian-imported cough syrups last year.
While Indian officials assert that the tainted syrups have not been exported and denied any evidence of illegal trading, the WHO is urging public health officials worldwide to intensify their scrutiny. They emphasized the importance of immediate reporting if these products are discovered within local markets.
Despite being the foremost supplier of low-cost medicines globally, India faces significant challenges in enforcing stringent manufacturing standards, particularly with smaller pharmaceutical companies. In a step toward accountability, Indian authorities have initiated a criminal investigation into the manufacturers involved. Additionally, the Tamil Nadu state government, where Sresan Pharmaceutical is located, has revoked the company’s operating license.
In light of the crisis, the Indian drug regulator has suspended production authorizations and has called for a recall of the implicated syrups. There is a push for heightened testing on raw materials and completed pharmaceuticals before they are released to the market, adhering to new safety assurances mandated by regional institutions.
The WHO has called upon national health authorities to enhance market surveillance, particularly with regards to unregulated supply chains that may be circulating these potentially dangerous medications undetected. The organization continues to collaborate closely with Indian health officials to trace the contamination’s origins and assess public health implications.
As governments and health organizations respond to this urgent public health threat, the necessity for robust oversight and quality assurance within pharmaceutical manufacturing is more critical than ever. The current incident presents a stark reminder of the vital importance of stringent regulations to protect vulnerable populations, especially children, from hazardous medical products.